Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleBasic Science Investigation

211At-Labeled Anti-CD45 Antibody as a Nonmyeloablative Conditioning for Canine DLA-Haploidentical Stem Cell Transplantation

Sofia H.L. Frost, Johnnie J. Orozco, Tom A. Bäck, Brian W. Miller, Erlinda B. Santos, Aimee Kenoyer, Sue E. Knoblaugh, Donald K. Hamlin, D. Scott Wilbur and Brenda M. Sandmaier
Journal of Nuclear Medicine July 2024, jnumed.124.267540; DOI: https://doi.org/10.2967/jnumed.124.267540
Sofia H.L. Frost
1Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johnnie J. Orozco
1Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington;
2Department of Medicine, University of Washington, Seattle, Washington;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tom A. Bäck
3Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian W. Miller
4Departments of Radiation Oncology and Medical Imaging, University of Arizona, Tucson, Arizona;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erlinda B. Santos
1Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aimee Kenoyer
1Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sue E. Knoblaugh
5Comparative Medicine Shared Resource, Fred Hutchinson Cancer Center, Seattle, Washington; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donald K. Hamlin
6Department of Radiation Oncology, University of Washington, Seattle, Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Scott Wilbur
6Department of Radiation Oncology, University of Washington, Seattle, Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brenda M. Sandmaier
1Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington;
2Department of Medicine, University of Washington, Seattle, Washington;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure
    • Download figure
    • Open in new tab
    • Download powerpoint
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Percentage of donor chimerism in granulocytes, MNCs, and CD3+ cells in dogs treated with 211At-anti-CD45 mAb conditioning in DLA-haploidentical HCT. Peripheral blood was taken from recipient dogs at serial time points and assessed for donor origin by polymerase chain reaction assay of polymorphic (CA)n dinucleotide repeats after extraction of genomic DNA from cells of interest, to calculate percentage donor chimerism in MNCs (A), granulocytes (B), or CD3+ T cells (C) over time. N.D. = not done.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Blood count recovery after 211At-CD45-B10 conditioning in DLA-haploidentical HCT. Peripheral blood from recipient dogs was drawn from baseline through HCT and followed up at serial time points to measure granulocytes (A), lymphocytes (B), and platelets (C). N.D. = not done.

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    Blood clearance and weekly chimerism by blood’s absorbed dose. (A) Blood samples were obtained at serial time points, and radioactivity measurements were made to estimate absorbed radiation dose (Gy) to blood for injected 211At activity. Animals receiving 0.75 mg/kg dose of mAb are indicated by dashed line, and animals receiving 0.50 mg/kg are indicated by solid line connecting solid circles. (B) Donor MNC chimerism by total absorbed radiation dose delivered to peripheral blood from weeks 1 to 6 after HCT. %ID = percentage injected dose.

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    211At distribution in lymph nodes taken from dog H700 at 2 different time points after 211At-CD45-B10 injection, as determined by α-camera imaging and hematoxylin and eosin staining of consecutive cryosections. Radioactivity was heterogeneously localized, predominantly to T-cell–rich regions in cortical follicles.

  • FIGURE 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5.

    Histopathology and immunohistochemistry staining on lymph nodes from dog H700, biopsied 2 and 19 h after 211At-CD45-B10 injection, showing that apoptosis progressed with time. Representative lymph node sections were stained with hematoxylin and eosin (H&E) and immunostained for T cells (CD3), apoptosis (cleaved caspase-3 [CC3]), and macrophages (MAC 387). Scale bar represents 100 μm.

Tables

  • Figures
    • View popup
    TABLE 1.

    Chimerism and Outcomes in DLA-Haploidentical HCT with 211At-Anti-CD45 mAb

    211At% donor MNC engraftment
    Dog no.MBq/kgmAb/kgMNC/kgCD34+/kgMaxDay 28FinalSurvival (d)Cause of death
    H70714.06 (0.380)0.7512.52.981766545CHV
    H71913.653 (0.369)0.7519.01.0100N.D.8223Intussusception, CHV
    H70023.199 (0.627)0.7510.93.987N.D.875Intussusception
    H6958.436 (0.228)0.52.90.755493194PTLD
    H83410.767 (0.291)0.56.21.777777283CHV
    H85610.767 (0.291)0.54.01.12724676Hemorrhage
    H76210.841 (0.293)0.514.53.3949268126PTLD
    H76511.359 (0.307)0.59.32.3866745182PTLD
    H75112.876 (0.348)0.510.32.7969095307End of study
    H69913.949 (0.377)0.513.02.594879163CHV
    H74113.986 (0.378)0.58.31.045N.D.4510Intussusception/CHV
    H76314.282 (0.386)0.54.92.473N.D.7310Hemorrhage
    H71414.504 (0.392)0.57.32.971N.D.7123Intussusception
    H76414.615 (0.395)0.54.81.2656542117Bronchiolitis
    H76614.8 (0.400)0.58.21.299969932Intussusception
    H50222.644 (0.612)0.515.96.3726822132PTLD
    H50522.792 (0.616)0.513.51.988838832Intussusception
    • At = astatine; max = maximum.

    • Data in parentheses are mCi/kg. Total of 17 dogs received 211At-anti-CD45 mAb. Initial donor engraftment was demonstrated in all subjects, with maximum chimerism ranging between 27% and 100%.

    • N.D. = not done.

    • View popup
    TABLE 2.

    Mean Absorbed Dose to Blood After Injection of 211At-Anti-CD45 mAb

    Dog no.mAb dose (mAb/kg)211At activity MBq (mCi)Absorbed dose to blood (Gy)Radiation dose/injected activity (Gy/MBq)
    H7000.75301 (8.135)4.300.014
    H7190.75108 (2.919)2.810.026
    H7070.75136 (3.676)2.280.017
    H6950.5105 (2.838)1.170.011
    H8340.5123 (3.324)1.090.009
    H8560.5107 (2.892)0.740.007
    H7620.5133 (3.595)1.680.013
    H7650.5109 (2.946)1.050.010
    H7510.5122 (3.297)1.690.014
    H6990.5121 (3.27)1.890.016
    H7410.5172 (4.649)1.040.006
    H7630.5156 (4.216)2.270.015
    H7140.5147 (3.973)1.580.011
    H7640.5159 (4.297)1.090.007
    H7660.5184 (4.973)2.220.012
    H502*0.5226 (6.108)N.D.N.D.
    H505*0.5227 (6.135)N.D.N.D.
    • ↵* Tissues for α-camera imaging and dosimetry were not collected from H502 and H505; thus, absorbed radiation doses were not determined.

    • N.D. = not done.

    • Data in parentheses are mCi.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 66 (6)
Journal of Nuclear Medicine
Vol. 66, Issue 6
June 1, 2025
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
211At-Labeled Anti-CD45 Antibody as a Nonmyeloablative Conditioning for Canine DLA-Haploidentical Stem Cell Transplantation
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
211At-Labeled Anti-CD45 Antibody as a Nonmyeloablative Conditioning for Canine DLA-Haploidentical Stem Cell Transplantation
Sofia H.L. Frost, Johnnie J. Orozco, Tom A. Bäck, Brian W. Miller, Erlinda B. Santos, Aimee Kenoyer, Sue E. Knoblaugh, Donald K. Hamlin, D. Scott Wilbur, Brenda M. Sandmaier
Journal of Nuclear Medicine Jul 2024, jnumed.124.267540; DOI: 10.2967/jnumed.124.267540

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
211At-Labeled Anti-CD45 Antibody as a Nonmyeloablative Conditioning for Canine DLA-Haploidentical Stem Cell Transplantation
Sofia H.L. Frost, Johnnie J. Orozco, Tom A. Bäck, Brian W. Miller, Erlinda B. Santos, Aimee Kenoyer, Sue E. Knoblaugh, Donald K. Hamlin, D. Scott Wilbur, Brenda M. Sandmaier
Journal of Nuclear Medicine Jul 2024, jnumed.124.267540; DOI: 10.2967/jnumed.124.267540
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • ACKNOWLEDGMENTS
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • The bone marrow niche and hematopoietic system are distinctly remodeled by CD45-targeted astatine-211 radioimmunotherapy
  • Google Scholar

More in this TOC Section

  • 212Bi-Macroaggregated Albumin Inhibited Mouse Melanoma Growth by Regulating Cell Cycle Checkpoint Markers Without Promoting Living Cell Repopulation
  • In Vivo Visualization and Quantification of Brain Heat Shock Protein 90 with [11C]HSP990 in Healthy Aging and Neurodegeneration
  • 161Tb Radioimmunotherapy as a Treatment for CD30-Positive Lymphomas
Show more Basic Science Investigation

Similar Articles

Keywords

  • radioimmunotherapy
  • 211At
  • haploidentical hematopoietic cell transplantation
  • canine
SNMMI

© 2025 SNMMI

Powered by HighWire